Literature DB >> 11821802

Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma.

Eisuke Adachi1, Shin-ichiro Maehara, Eiji Tsujita, Ken-ichi Taguchi, Shin-ichi Aishima, Tatsuya Rikimaru, Yo-ichi Yamashita, Shinji Tanaka.   

Abstract

BACKGROUND: The long-term prognosis after resection for patients with hepatocellular carcinoma is still unsatisfactory because of the high recurrence rate. The survival of patients with multiple intrahepatic or extrahepatic recurrence is especially poor.
METHODS: Among the patients who underwent hepatic resection for hepatocellular carcinoma between 1981 and 2000, 216 patients with 3 or less than 3 intrahepatic recurrences (group B); 156 patients with more than 3 intrahepatic recurrences, extrahepatic recurrences, or both (group C); and 51 patients who survived more than 5 years without recurrence (group A) were clinicopathologically studied.
RESULTS: The period to recurrence of group C was significantly earlier than that of group B and also showed a significantly poor prognosis after recurrence. Tumor factors, including size, portal venous invasion, intrahepatic metastasis, histologic grade, or the number of tumors at resection in group C was significantly worse than in groups A and B. Although no differences are recognized in the tumor factors between groups A and B, except for the alpha-fetoprotein level, liver function in group B was significantly worse than that in group A. In addition, the frequency of hepatitis B surface antigen in group B and that of hepatitis C virus in group B was significantly less and higher than that in group A, respectively.
CONCLUSION: Similar to extrahepatic metastasis, multinodular recurrences are also mainly caused by metastatic recurrence from the main tumor by means of the portal system, and recurrences with up to 3 intrahepatic nodules are mainly caused by metachronous multicentric hepatocarcinogenesis. Because the mechanisms of recurrence differed, determining the patterns of recurrence on the basis of the clinicopathologic findings is important for selecting the optimal postoperative therapy for each individual patient.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821802     DOI: 10.1067/msy.2002.119496

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  14 in total

1.  Identification and expression profiles of genes and protens in SMMC-7721 cells.

Authors:  Xie Shun Feng; Sun Shu Ming; Lu Xiao Feng; Xie Ze Feng
Journal:  Mol Biol Rep       Date:  2014-01-09       Impact factor: 2.316

2.  Portal hypertension: contraindication to liver surgery?

Authors:  Lorenzo Capussotti; Alessandro Ferrero; Luca Viganò; Andrea Muratore; Roberto Polastri; Hedayat Bouzari
Journal:  World J Surg       Date:  2006-06       Impact factor: 3.352

3.  Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated?

Authors:  Andrea Ruzzenente; Alessandro Valdegamberi; Tommaso Campagnaro; Simone Conci; Silvia Pachera; Calogero Iacono; Alfredo Guglielmi
Journal:  World J Gastroenterol       Date:  2011-12-14       Impact factor: 5.742

4.  18F-FDG-PET/CT predicts the distribution of microsatellite lesions in hepatocellular carcinoma.

Authors:  Hironori Ochi; Masashi Hirooka; Atsushi Hiraoka; Yohei Koizumi; Masanori Abe; Ichiro Sogabe; Yoshihiro Ishimaru; Keizou Furuya; Masao Miyagawa; Hideki Kawasaki; Kojiro Michitaka; Yasutsugu Takada; Teruhito Mochizuki; Yoichi Hiasa
Journal:  Mol Clin Oncol       Date:  2014-06-25

Review 5.  CYP3A4 Gene Is a Novel Biomarker for Predicting a Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Ryo Ashida; Yukiyasu Okamura; Keiichi Ohshima; Yuko Kakuda; Katsuhiko Uesaka; Teiichi Sugiura; Takaaki Ito; Yusuke Yamamoto; Takashi Sugino; Kenichi Urakami; Masatoshi Kusuhara; Ken Yamaguchi
Journal:  Cancer Genomics Proteomics       Date:  2017 Nov-Dec       Impact factor: 4.069

6.  Relationship between microvessel count and post-hepatectomy survival in patients with hepatocellular carcinoma.

Authors:  Atsushi Nanashima; Toshiyuki Nakayama; Yorihisa Sumida; Takafumi Abo; Hiroaki Takeshita; Kenichirou Shibata; Shigekazu Hidaka; Terumitsu Sawai; Toru Yasutake; Takeshi Nagayasu
Journal:  World J Gastroenterol       Date:  2008-08-21       Impact factor: 5.742

7.  Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.

Authors:  Rosalba D'Alessandro; Maria Grazia Refolo; Catia Lippolis; Nicola Carella; Caterina Messa; Aldo Cavallini; Brian Irving Carr
Journal:  Cell Oncol (Dordr)       Date:  2018-02-22       Impact factor: 6.730

8.  Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma.

Authors:  Michelle Z Xu; Tzy-Jyun Yao; Nikki P Y Lee; Irene O L Ng; Yuk-Tat Chan; Lars Zender; Scott W Lowe; Ronnie T P Poon; John M Luk
Journal:  Cancer       Date:  2009-10-01       Impact factor: 6.860

9.  Outcomes of hepatic resection for a single large hepatocellular carcinoma.

Authors:  Yong Beom Cho; Kuhn Uk Lee; Hae Won Lee; Eung-Ho Cho; Sung-Hoon Yang; Jai Young Cho; Nam-Joon Yi; Kyung-Suk Suh
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

10.  A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse.

Authors:  Federica Pedica; Andrea Ruzzenente; Fabio Bagante; Paola Capelli; Ivana Cataldo; Serena Pedron; Calogero Iacono; Marco Chilosi; Aldo Scarpa; Matteo Brunelli; Anna Tomezzoli; Guido Martignoni; Alfredo Guglielmi
Journal:  PLoS One       Date:  2013-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.